AACR 2020 Virtual Conference Session II June 22- 24, 2020

Full program: https://www.aacr.org/meeting/aacr-annual-meeting-2020/virtual-meeting-ii-program/

AACR News

Michelle Le Beau, PhD, Arthur and Marian Edelstein Professor of Medicine, Director of the University of Chicago Medicine Comprehensive Cancer Center is the 2020 recipient of the AACR – Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research.

Read the AACR press release here, At the Forefront article here, and the UChicago Medicine announcement here.

Events

June 23, 2020 5:15-6PM ET/4:15-5PM CT

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Lecture Therapy-related myeloid neoplasms: When genetics and environment collide
Michelle Le Beau

Oral Presentations


Session MS.IM02.03 - Immunomodulatory Agents and Interventions 1072 - Lymphangiogenesis-inducing vaccines for melanoma treatment elicit potent tumor-specific T cell immunity and long-term tumor control Maria Stella Sasso...Melody Swartz.


Session MS.IM02.04 - Novel Immunotherapies and Mechanisms 5695 - Induction of lymphangiogenesis in breast cancer enhances responsiveness to immunotherapies Peyman Hosseinchi...Melody Swartz.

June 24, 2020 10:20-30AM ET/9:20-9:30 CT
#AACR20 Virtual Meeting

Session MS.IM02.02 - Combination Immunotherapies
3417 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort
Young Kwang Chae...Blase Polite...Razelle Kurzrock.

June 24, 2020 2:15-35PM ET/1:15-35PM CT

Session MW12 - Emerging Models: Bring in the Engineers
In vitro models of the tumor-immune interface
Melody Swartz.

June 24, 2020 5:30-50PM ET/4:30-50PM CT

Session ED37 - Radiation and Immunotherapy
Radiotherapy and immunotherapy in oligometastatic disease
Ralph Weichselbaum.

Poster Presentations

Available starting June 22, 2020 9AM/ET 8AM CT

Note: Links to PDFs of posters will be available through the AACR website and will be accompanied by an audio description.

Session PO.EP01.08 - Genetics, Genomics, Polygenic Score, and Risk Prediction
2320 / 4 - Evaluating a polygenic risk score for breast cancer in women of African ancestry
Zhaohui Du...Olufunmilayo Olopade...Christopher A. Haiman.

Session PO.EP01.07 - Breast Cancer
4613 / 1 - Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry
Babatunde Adedokun...Olufunmilayo Olopade...Dezheng Huo.

Session PO.MCB05.01 - DNA Methylation
160 / 24 - Identifying differential methylation patterns of benign and tumor prostate tissue in African American and European American prostate cancer patients
Meytal B. Chernoff...Brandon Pierce.

Session PO.PR03.01 - Implementation Science
5748 / 13 - Declines in health-related quality of life among older patients diagnosed with hematologic malignancies
Ashwini Zolekar...Brian Chiu...Gregory S. Calip.

Session PO.EP01.04 - Integrative Genomics
28 / 1 - Integrating genomic and transcriptomic data to identify genetic loci associated with breast cancer risk in women of African ancestry
Guochong Jia...Dezheng Huo...Olufunmilayo Olopade...Wei Zheng.
Session PO.IM02.16 - Immune Response to Therapies 1
5535 / 25 - SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors
Haley Neff-LaFord...Thomas Gajewski...Andrew L. Coveler.

Session PO.CL01.04 - Tumor Type-focused Translational Research Specific
5451 / 29 - Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response
Erik Dvergsten...Russell Szmulewitz, Michael L. Maitland.

Session PO.TB07.02 - Novel Tumor Imaging Techniques and Probes
1646 / 7 - Preclinical oxygen imager for cancer oxygenation studies
Boris Epel, Howard Halpern, Mrignaayni Kotecha.

Session LBPO.TB03 - Late-Breaking Research: Tumor Biology 3
LB-370 / 22 - Whole-genome analysis of breast cancer patients from Nigeria reveals ethnic-specific evolution of somatic alterations and significant intratumoral heterogeneity
Naser Ansari-Pour...Olufunmilayo Olopade.

Session VM2PO.CT01 - Phase I Clinical Trials
CT162 - The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)
Ulrich Jaeger...Peter Riedell...Edmund K. Waller.

Session PO.IM02.13 - Immune Mechanisms Invoked by Therapies 2
2253 / 6 - Lymphangiogenesis augments the anti-tumor efficacy of radiotherapy in mouse melanoma
Nikolaos Mitrousis, Maria Stella Sasso, Ralph Weichselbaum...Melody Swartz.

Session PO.TB10.02 - Methods to Measure Tumor Evolution and Heterogeneity
2697 / 15 - Single cell RNA sequencing and tumor cell heterogeneity in metastatic triple-negative breast cancer
Dongbo Yang...Marsha Rosner.

Session PO.CL01.03 - New Technologies and Other Translational Studies
4263 / 17 - Characterization of patient-specific drug delivery for breast cancer using image-guided computational fluid dynamics
Chengyue Wu...Gregory S. Karczmar...Thomas E. Yankeelov.

Session PO.IM01.02 - Immunogenomics
4492 / 5 - Characterization of the T-Cell receptor repertoire in patients with acute myeloid leukemia treated with 5-Azacytidine plus chemotherapy
John Beckford...Wendy Stock...Houda Alachkar.

Session PO.TB04.07 - Metastasis Therapies
5038 / 25 - Limited inhibition of multiple nodes in a driver network blocks metastasis
Ali Ekrem Yesilkanal... **Marsha Rosner.**

Session PO.BSB01.01 - Actionable Feature Detection in NGS and Omics
5468 / 16 - **Gene fusions in breast cancer in Nigerian women**
Anna Elizabeth Woodward... **Olufunmilayo Olopade.**

Session PO.PR03.01 - Implementation Science
5749 / 14 - **The association between physical health-related quality of life, physical functioning and risk of contralateral breast cancer**
Nita Mukand... **Brian Chiu**... Gregory S. Calip.

Session PO.TB07.03 - New Imaging-based Approaches to Plan, Monitor, and Augment Cancer Treatment
2773 / 5 - **Increased tumor control boosting hypoxic regions identified with EPR pO2 imaging in 2 tumor types**
Howard Halpern... Bülent Aydogan, Ralph Weichselbaum... Boris Epel.

Session PO.MCB04.01 - Gene Regulation and Transcription Factors 1
1290 / 13 - **Role of NNMT-regulated m6A mRNA modification in triple-negative breast cancer oncogenic gene expression**
Deniz N. Dolcen... **Chuan He**, Suzanne D. Conzen.

Session PO.TB07.02 - Novel Tumor Imaging Techniques and Probes
1648 / 9 - **Multimodal imaging of tumor hypoxia with 18F-misonidazole PET, EPR, and MRI**
Inna Gertsenshteyn... **Gregory Karczmar**... Chin-Tu Chen, Howard Halpern.

Session PO.IM02.03 - Adoptive Cell Therapy 3
3238 / 10 - **Engineering chimeric antigen receptors for adoptive T cell therapy of cancers that express the Tn antigen**
Preeti Sharma... **Hans Schreiber**, David M. Kranz.

Session PO.MCB08.05 - The Warburg Effect
5989 / 1 - **Metabolic heterogeneity of the tumor microenvironment**
Bradley I. Reinfeld... **Alex Muir**... W. Kimryn Rathmell.

Session PO.ET01.02 - Novel Therapeutic Approaches
6428 / 22 - **Imputing a more selective therapy: Identifying Wee1 and XPO1 inhibitors for TNBC**
Robert F. Gruener... **Geoffrey Greene**, R. Stephanie Huang.

Session PO.CH01.02 - Targeted Delivery of Small Molecules and Biologics 1
1729 / 15 - **Novel liposomal topotecan formulation has a lower IC50 than the free form on neuroblastoma cells**
Paula Viza Gomes... **Jessica Kandel**... Sonia L. Hernandez.

Session PO.EN02.01 - Molecular, Preclinical, and Clinical Endocrinology 2
4370 / 13 - **Lasofoxifene alone or in combination with palbociclib as an effective treatment for therapy-resistant ER-positive metastatic breast cancer**
Muriel Laine... **Geoffrey Greene.**
Session PO.EN02.01 - Molecular, Preclinical, and Clinical Endocrinology 2
4374 / 17 - **CE+BZA combination therapy decreases breast cancer outgrowth in part through activation of the AHR pathway**
Anna G. Dembo...Geoffrey Greene.

Session PO.BSB01.06 - Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging
4428 / 23 - **Characterizing the tumor-infiltrating T-cell repertoire of breast cancer in indigenous African patients from Southwest Nigeria**
Jean-Baptiste Reynier...Olufunmilayo Olopade.

Session PO.IM02.22 - Vaccines
4582 / 22 - **Tumor matrix-targeted polymeric glyco-adjuvant for in situ cancer vaccination**
Laura T. Gray...Melody Swartz, Jeffrey Hubbell.

Session PO.CL01.01 - Translational Research with Targeted Therapies
799 / 6 - **CDKN2A mutation predicts immunotherapy resistance in stage III/IV NSCLC**
Stanley I. Gutiontov, Sean Pitroda.